跳至主要内容
临床试验/NCT02516449
NCT02516449已完成不适用

Utility of Two Patients Decision Aids About Asthma Inhaled Controller Medication Use in Adult Patients With Asthma

Laval University2 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2013年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
51
试验地点
2
主要终点
Change from baseline in asthma knowledge at 2 months, measured by QCALF score

研究概览

简要总结

The purpose of this study is to determine whether the use of shared decision making aids is more effective than usual care in improving asthma knowledge, lessening decisional conflict, and enhancing adherence to treatments and asthma control in adult patients with mild to severe asthma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women, aged 18 to 65 years;
  • Current diagnosis of mild to severe asthma; 2.1) Asthma diagnosis will be made upon one of the following criteria: 2.1.1) Forced expiratory volume in one second (FEV1) increases by at least 12% after the use of a bronchodilator (and a minimum ≥ 200 mL); 2.1.2) Current asthma symptoms and a positive methacholine challenge test (20% fall in FEV1 after inhalation of a provocative dose of methacholine 16 mg/mL); 2.1.3) A respirologist's current diagnosis of asthma found in the patient's medical report. 2.2) Severity of asthma will be assessed according to prescribed pharmacotherapy, as suggested by the 2012 Canadian Thoracic Society Guidelines: 2.2.1) Patients with mild asthma using SABA as well as low doses (≤250 mcg/day beclomethasone or equivalent) of inhaled glucocorticosteroids; 2.2.2) Patients with moderate asthma using SABA as well as low to moderate doses (250mcg/day < dose ≤500 mcg/day beclomethasone or equivalent) of inhaled glucocorticosteroids, with or without additional therapy (LABA or LTRA); 2.2.3) Patients with severe asthma using high doses (>500 mcg/day beclomethasone or equivalent) of inhaled glucocorticosteroids, and additional pharmacotherapy (LABA, LTRA, or Prednisone), and SABA.

排除标准

  • Chronic obstructive pulmonary disease (COPD);
  • Education on asthma in the last 6 months.

结局指标

主要结局

Change from baseline in asthma knowledge at 2 months, measured by QCALF score

时间窗: Visit 1 (baseline) and visit 2 (2-month follow-up)

Change from baseline in decisional conflict at 2 months, measured by DCS score

时间窗: Visit 1 (baseline) and visit 2 (2-month follow-up)

次要结局

  • Change from baseline in adherence to treatment at 2 months, measured by questionnaire(Visit 1 (baseline) and visit 2 (2-month follow-up))
  • Change from baseline in asthma control at 2 months, measured by ACSS score(Visit 1 (baseline) and visit 2 (2-month follow-up))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Louis-Philippe Boulet

MD FRCPC FCCP

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

研究点 (2)

Loading locations...

相似试验